

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	09/928,213
Filing Date	August 10, 2001
First Named Inventor	SHANKARA, Srinivas
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	GA0197C

(use as many sheets as necessary)

Sheet 1 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,770,428	06-23-98	Wisconsin Alumni Research Foundation	
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			
	11	US-			
	12	US-			
	13	US-			
	14	US-			
	15	US-			
	16	US-			
	17	US-			
	18	US-			
	19	US-			
	20	US-			

**RECEIVED**

OCT 30 2002

TECH CENTER 1680/2900

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	21	WO 97/34613	09-25-97	U of Virginia Patent Foundation		
	22	WO 98/43677	10-08-98	Institut Pasteur		
	23					
	24					
	25					
	26					
	27					
	28					
	29					


Examiner  
SignatureDate  
Considered

1/12/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 749A

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

### Complete if Known

Application Number	09/928,213
Filing Date	August 10, 2001
First Named Inventor	SHANKARA, Srinivas
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	GA0197C

RECEIVED

OCT 30 2002

TECH CENTER 1600/29

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
[Signature]	30	KANG, X. et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins", Cancer Research, January 1997, 57:202-205	
	31	KOZONO, H. et al., "Production of soluble MHC class II proteins with covalently bound single peptides", Nature, May 1994, 369:151-154	
	32	MOTTEZ, E. et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic", The Journal of Experimental Medicine, February 1995, 181:493-502	
	33	POSNETT, D.N. et al., "A Novel Method for Producing Anti-peptide Antibodies", The Journal of Biological Chemistry, February 1988, 263(4):1719-1725	
	34	SAKAI, C. et al., "Melanosomal proteins as melanoma-specific immune targets", Melanoma Research, 1997, 7:83-95	
	35	TAM, James P., "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system", The Proceedings of National Academy of Science, August 1988, 85:5409-5413	
	36	TSAL, V. et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells", The Journal of Immunology, 1997, 158:1796-1802	
	37	ARONOV, S. et al., "Identification of 3'UTR Region Implicated in Tau mRNA Stabilization in Neuronal Cells", Journal of Molecular Neuroscience, 1999, 12:131-145	
	38	HOLCIK, M. and LIEBHABER, S.A., "Four highly stable eukaryotic mRNAs assemble 3' untranslated region RNA-protein complexes sharing cis and trans components", The Proceedings of the National Academy of Science, March 1997, 94:2410-2414	
	39	McGOWAN, K.M. et al., "Tumor Necrosis Factor-alpha Regulation of Glucose Transporter (GLUT1) mRNA Turnover", The Journal of Biological Chemistry, January 1997, 272(2):1331-1337	
[Signature]	40	WANG, X. and LIEBHABER, S.A., "Complementary change in cis determinants and trans factors in the evolution of an mRNP stability complex", The EMBO Journal, 1996, 15(18):5040-5051	

Examiner  
Signature

[Signature]

Date  
Considered

1/12/04

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/928,213
Filing Date	August 10, 2001
First Named Inventor	SHANKARA, Srinivas
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	GA0197C

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	HEEMSKERK, M. et al., "Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells", Cellular Immunology, 1999, 195:10-17	
	2	TOES, R. et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion", The Proceedings of the National Academy of Science, December 1997, 94:14660-14665	
	3	WHITTON, J. et al., "A 'String-of-Beads' Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", Journal of Virology, January 1993, 348-352	

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

Examiner  
SignatureDate  
Considered

1/12/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.